

Dear Doctor,

You are cordially invited to a dinner symposium on

How are the latest developments in drug development going to impact the treatment of psychiatric illnesses in the future?

Date: 2nd Dec 2009

Venue: Crystal Jade Golden Palace Restaurant
Paragon Singapore
290 Orchard Road #05-22
Singapore 238859

Programme

7.00 pm Registration

7.20 pm How are the latest developments in drug development going to impact the treatment of psychiatric illnesses in the future?

Prof Amir Kalali

Vice President, Medical and Scientific Services and Global Therapeutic Team Leader CNS, Quintiles
Founding chairman, International Society for CNS Drug Development
Professor of Psychiatry at University of California San Diego

8.10 pm Q & A followed by Dinner

CME points pending application

Amir Kalali, MD



Amir Kalali, M.D., is Vice President of Medical and Scientific Services and Global Therapeutic Team Leader CNS at Quintiles, focuses on developing novel compounds for the treatment of disorders of the central nervous system, and is responsible for the medical and scientific aspects of development programs in psychiatry and neurology for Quintiles globally. He is an expert in CNS clinical trial methodology.

Dr. Kalali was founding chairman of the executive committee of the International Society for CNS Drug Development and serves as its executive secretary, facilitating scientific collaboration among scientists in academia, government and the pharmaceutical industry.

Dr. Kalali is also Professor of Psychiatry at University of California San Diego. Widely published, he sits on the editorial board of several professional journals and edits *Psychiatry*. *PharmaVOICE* magazine twice named him one of its 100 most inspiring leaders in the life sciences.

Dr. Kalali received his M.D. from the University of London and completed his psychiatry training at University College and Middlesex School of Medicine, London University. A member of many professional organizations, Dr. Kalali regularly presents at national and international scientific meetings, and lectures frequently on psychopharmacological and drug development topics.

Organised by:

Supported by:

AstraZeneca 

